Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

By Siddhi Mahatole Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Medical device company ResMed (NYSE:RMD) in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...

ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

ResMed (NYSE:RMD) supports global respiratory care as s&p 500 chart discussions frame large healthcare organizations.

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

RMD is set to report Q2 results on Jan. 29, with revenues likely to jump 8.3% and EPS 10.3% as masks, devices and software drive growth.